Briciclib
Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors[1].
Product Specifications
CAS Number
865783-99-9
Product Name Alternative
ON 014185
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Caspase; CDK; c-Myc; Eukaryotic Initiation Factor (eIF) ; MDM-2/p53
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Briciclib.html
Concentration
10mM
Purity
99.45
Solubility
DMSO : ≥ 31 mg/mL
Smiles
O=S(CC1=CC(OP(O)(O)=O)=C(OC)C=C1)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O
Molecular Formula
C19H23O10PS
Molecular Weight
474.42
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
EIF4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
